Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Twist Bioscience Corporation TWST

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throu...

Recent & Breaking News (NDAQ:TWST)

Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery

Business Wire March 25, 2021

Twist Bioscience and Biotia Receive U.S. FDA Emergency Use Authorization for First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay

Business Wire March 24, 2021

Twist Bioscience Functional GLP-1R Antibodies Identified From Its Proprietary Synthetic DNA GPCR Libraries Demonstrate Potent Blood Glucose Control

Business Wire March 22, 2021

Twist Bioscience Begins Shipping of Synthetic RNA Controls for B.1.351 and P.1 Variants

Business Wire March 15, 2021

Twist Bioscience Named to Fast Company's Annual List of the World's Most Innovative Companies for 2021

Business Wire March 9, 2021

Twist Bioscience and Watchmaker Genomics Announce Partnership to Drive New Applications of High-throughput Genetic Sequencing

Business Wire March 2, 2021

Twist Bioscience to Highlight Genotyping by Sequencing and Methylation Solution During AGBT

Business Wire March 1, 2021

Twist Bioscience Launches Industry-Leading NGS Methylation Detection System for Liquid Biopsy Cancer Analysis and Epigenetic Studies

Business Wire February 24, 2021

Twist Bioscience and Berry Genomics to Offer New NGS Solution to Advance Research and Precision Medicine

Business Wire February 22, 2021

Twist Bioscience to Present at Upcoming Virtual Conferences

Business Wire February 19, 2021

Twist Bioscience and Victorian Clinical Genetic Services Collaborate on Development of Novel Whole Exome Capture Diagnostic Assay

Business Wire February 18, 2021

Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results

Business Wire February 4, 2021

Twist Bioscience Announces Executive Team Appointments

Business Wire February 3, 2021

Twist Bioscience to Report Fiscal 2021 First Quarter Financial Results on Thursday, February 4, 2020

Business Wire January 28, 2021

Twist Bioscience Signs Two Biopharma Technology Agreements to Enable Novel Therapeutics Discovery

Business Wire January 19, 2021

Twist Bioscience Begins Shipping of Synthetic RNA Controls for UK Variant Strain of SARS-CoV-2

Business Wire January 14, 2021

SKB finalizes new lease agreement with Twist Bioscience Corporation ("Twist") at recently repositioned mixed-use campus, ParkWorks Industrial Center

PR Newswire January 11, 2021

Twist Bioscience Supplies Centers for Disease Control and Prevention with Custom SARS-CoV-2 Synthetic RNA Controls

Business Wire January 7, 2021

Twist Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2021

Twist Bioscience to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2

Business Wire December 23, 2020